The importance of drug target selection capability for new drug innovation: definition, fostering process, and interaction with organizational management

If you have found this article useful and you think it is important that researchers across the world have access, please consider donating, to ensure that this valuable collection remains Open Access.

Prometheus is published by Pluto Journals, an Open Access publisher. This means that everyone has free and unlimited access to the full-text of all articles from our international collection of social science journals. Furthermore Pluto Journals authors don’t pay article processing charges (APCs).

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Header Abstract Content Author and article information References Comments

Prometheus

Volume 36, Issue 2

Record: found
Abstract: found
Article: found

Is Open Access

The importance of drug target selection capability for new drug innovation: definition, fostering process, and interaction with organizational management

Published

research-article

Author(s): Ryo Okuyama , Masaharu Tsujimoto

Publication date (Print): 1 June 2020

Journal: Prometheus

Publisher: Pluto Journals

Bookmark

Abstract

Content

Author and article information

Contributors

Ryo Okuyama

Journal

Journal ID (doi): 10.2307/j50022063

Journal ID (jcode): prometheus

Title: Prometheus

Publisher: Pluto Journals

ISSN: 0810-9028

ISSN: 1470-1030

Publication date (Print): 1 June 2020

Volume: 36

Issue: 2 ( doiID: 10.13169/prometheus.36.issue-2 )

Pages: 135-152

Affiliations

Department of Innovation Science, School of Environment and Society, Tokyo Institute of Technology, Tokyo 108-0023, Japan

Article

Publisher ID: prometheus.36.2.0135

DOI: 10.13169/prometheus.36.2.0135

SO-VID: 7a8f6f20-07ce-47f8-875c-60149fc19d58

License:

All content is freely available without charge to users or their institutions. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission of the publisher or the author. Articles published in the journal are distributed under a http://creativecommons.org/licenses/by/4.0/.

History

Custom metadata

lang eng

ScienceOpen disciplines: Computer science,Arts,Social & Behavioral Sciences,Law,History,Economics

References

Apriliyanti, I. and Alon, I. (2017) ‘Bibliometric analysis of absorptive capacity’, International Business Review, 26, pp.896–907.
Baba, Y., Shichijo, N. and Sedita, S. (2009) ‘How do collaborations with universities affect firms’ innovative performance? The role of “Pasteur scientists” in the advanced materials field', Research Policy, 38, 5, pp.756–64.
Bioscience Innovation and Growth Team (2004) Bioscience 2015 Entire Executive Summary, available from www.bioindustry.org/bigtreport/index2.html (accessed November 2011).
Cockburn, I. and Henderson, R. (1996) ‘Public-private interaction in pharmaceutical research’, Proceedings of the National Academy of Sciences, 93, 239, pp.12725–30.
Cockburn, I. and Henderson, R. (1998) ‘Absorptive capacity, coauthoring behavior, and the organization of research in drug discovery’, Journal of Industrial Economics, 46, 2, pp.157–82.
Cohen, W. and Levinthal, D. (1990) ‘Absorptive capacity: a new perspective on learning and innovation’, Administrative Sciences Quarterly, 35, pp.569–96.
Comroe, J. and Dripps, R. (1976) ‘Scientific basis for the support of biomedical science’, Science, 192, 4235, pp.105–11.
Cook, D., Brown D., Alexander, R. et al. (2014) ‘Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework’ Nature Reviews Drug Discovery, 13, pp.419–31.
DiMasi, J., Feldman, L., Seckler, A. and Wilson, A. (2010) ‘Trends in risks associated with new drug development: success rates for investigational drugs’, Clinical Pharmacology and Therapeutics, 87, pp.272–7.
Dimitrov, D. and Marks, J. (2009) ‘Therapeutic antibodies: current state and future trends – is a paradigm change coming soon?‘, Methods in Molecular Biology, 525, pp. 1–27.
Edmondson, A. and McManus, S. (2007) ‘Methodological fit in management field research’, Academy of Management Review, 32, 4, pp.1246–64.
Eisenhardt, K. and Graebner, M. (2007) ‘Theory building from cases: opportunities and challenges’, Academy of Management Journal, 50, 1, pp.25–32.
Erlanson, D., Fesik, S., Hubbard, R. et al. (2016) ‘Twenty years on: the impact of fragments on drug discovery’, Nature Reviews Drug Discovery, 15, 9, pp.605–19.
Fabrizio, K. (2009) ‘Absorptive capacity and the search for innovation’, Research Policy, 38, 2, pp.255–67.
Fabrizio, K. and Di Minin, A. (2008) ‘Commercializing the laboratory: faculty patenting and the open science environment’, Research Policy, 37, 5, pp.914–31.
Folkersen, L., Biswas, S., Frederiksen, K. et al. (2015) ‘Applying genetics in inflammatory disease drug discovery’, Drug Discovery Today, 20, 10, pp.1176–81.
Furukawa, R. and Goto, A. (2006) ‘The role of corporate scientists in innovation’, Research Policy, 35, 1, pp.24–36.
Galizzi, J., Lockhart, B. and Bril, A. (2013) ‘Applying systems biology in drug discovery and development’, Drug Metabolism and Drug Interactions, 28, 2, pp.67–78.
Gittelman, M. (2016) ‘The revolution re-visited: clinical and genetics research paradigms and the productivity paradox in drug discovery’, Research Policy, 45, 8, pp.1570–85.
Gittelman, M. and Kogut, B. (2003) ‘Does good science lead to valuable knowledge? Biotechnology firms and the evolutionary logic of citation patterns’, Management Science, 49, 4, pp.366–82.
Hertzberg, R. and Pope, A. (2000) ‘High-throughput screening: new technology for the 21st century’, Current Opinion in Chemical Biology, 4, 4, pp.445–51.
Hess, A. and Rothaermel, F. (2011) ‘When are assets complementary? Star scientists, strategic alliances, and innovation in the pharmaceutical industry’, Strategic Management Journal, 32, 8, pp.895–909.
Hirano, T., Yasukawa, K., Harada, H. et al. (1986) ‘Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin’, Nature, 324, 6092, pp.73–6.
Holmes, A., Bonner, F. and Jones, D. (2015) ‘Assessing drug safety in human tissues – what are the barriers?‘, Nature Reviews Drug Discovery, 14, pp.585–7.
Japanese Society of Interferon and Cytokine Research (2010) Cytokine Hunting, Kyoto University Press, Kyoto (in Japanese).
Kirchmair, J., Göller, A., Lang, D. et al. (2015) ‘Predicting drug metabolism: experiment and/or computation?‘, Nature Reviews Drug Discovery, 14, pp.387–404.
Kishimoto, T. (2005) ‘Interleukin-6: from basic science to medicine – 40 years in immunology’, Annual Review of Immunology, 23, pp.1–21.
Kishimoto, T. and Nakashima, A. (2007) Present Immunology Stories, Kodansha Publishing, Tokyo (in Japanese).
Kishimoto, T. and Nakashima, A. (2009) Miracle of Antibody Medicine and Innate Immunity, Kodansha Publishing, Tokyo (in Japanese).
Kuwashima, K. (2006) Management of Uncertainty, Nikkei BP Publishing, Tokyo (in Japanese).
Morgan, P., Brown, D., Lennard, S. et al. (2018) ‘Impact of a five-dimensional framework on R&D productivity at AstraZeneca’, Nature Reviews Drug Discovery, 17, pp.167–81.
Munos, B. (2009) ‘Lessons from 60 years of pharmaceutical innovation’, Nature Reviews Drug Discovery, 8, pp.959–68.
Munos, B. (2016) ‘Biomedical innovation: lessons from the past and perspectives for the future’, Clinical Pharmacology and Therapeutics, 100, 6, pp.588–90.
Nadeau, J. and Dudley, A. (2011) ‘Systems genetics’, Science, 331, pp.1015–16.
Nagano, K. and Higashisaka, K. (2016) ‘Promotion of drug discovery research by utilizing omics technology’, Yakugaku Zasshi, 136, 2, pp.143–4.
Nagaoka, S. (2016) New Drug Discovery and Development, Nikkei BP Publishing, Tokyo (in Japanese).
Nishimoto, N. (2006) ‘Interleukin-6 in rheumatoid arthritis’, Current Opinion of Rheumatology, 18, 3, pp.277–81.
Ohsugi, Y. (2007) ‘Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody) unveils the mysterious etiology of immune-mediated inflammatory diseases’, Biological and Pharmaceutical Bulletin, 30, 11, pp.2001–6.
Ohsugi, Y. (2013) Birth of New Drug Actemra, Iwanami Shoten Publishing, Tokyo (in Japanese).
Okuyama, R. (2017) ‘Importance of tacit knowledge in incremental innovation: implications from drug discovery cases’, Journal of Strategy and Management, 10, 1, pp.118–30.
Plymoth, A. and Hainaut, P. (2011) ‘Proteomics beyond proteomics: toward clinical applications’, Current Opinion in Oncology, 23, 1, pp.77–82.
Powell, W., Koput, K. and Smith-Doerr, L. (1996) ‘Interorganizational collaboration and the locus of innovation: networks of learning in biotechnology’, Administrative Science Quarterly, 41, 1, pp.116–45.
Rosenberg, N. and Nelson, R. (1994) ‘American universities and technological advance in industry’, Research Policy, 23, 3, pp.323–48.
Savino, R., Paduano, S., Preianò, M. and Terracciano, R. (2012) ‘The proteomics big challenge for biomarkers and new drug-targets discovery’, International Journal of Molecular Sciences, 13, 11, pp.13926–48.
Scannell, J. Blanckley, A., Boldon, H. and Warrington, B. (2012) ‘Diagnosing the decline in pharmaceutical R&D efficiency’, Nature Reviews Drug Discovery, 11, pp.191–200.
Smietana, K., Siatkowski, M. and Moller, M. (2016) ‘Trends in clinical success rates’, Nature Reviews Drug Discovery, 15, pp.379–80.
Stokes, D. (1997) Pasteur's Quadrant: Basic Science and Technological Innovation, Brookings Institution, Washington, DC.
Stranger, B., Stahl, E. and Raj, T. (2011) ‘Progress and promise of genome-wide association studies for human complex trait genetics’, Genetics, 187, pp.367–83.
Swinney, D. and Anthony, J. (2011) ‘How were new medicines discovered?‘, Nature Reviews Drug Discovery, 10, pp.507–19.
Tralau-Stewart, C., Wyatt, C., Kleyn, D. and Ayad, A. (2009) ‘Drug discovery: new models for industry–academic partnerships’, Drug Discovery Today, 14, 1/2, pp.95–101.
Toole, A. (2012) ‘The impact of public basic research on industrial innovation: evidence from the pharmaceutical industry’, Research Policy, 41, 1, pp.1–12.
Varmus, H. (2010) ‘Ten years on – the human genome and medicine’, New England Journal of Medicine, 362, 21, pp.2028–9.
Van der Sijde, M., Ng, A. and Fu, J. (2014) ‘Systems genetics: from GWAS to disease pathways’, Biochimica et Biophysica Acta, 1842, 10, pp.1903–9.
Yan, S., Liu, R., Jin, H. et al. (2015) ‘“Omics” in pharmaceutical research: overview, applications, challenges, and future perspectives’, Chinese Journal of Natural Medicines, 13, 1, pp.3–21.
Zahra, S. and George, G. (2002) ‘Absorptive capacity: a review, reconceptualization, and extension’, Academy of Management Review, 27, 2, pp.185–203.
Zucker. L., Darby, M. and Armstrong, J. (2002) ‘Commercializing knowledge: university science, knowledge capture, and firm performance in biotechnology’, Management Science, 48, 1, pp.138–53.

Comments

Comment on this article

[1] Apriliyanti, I. and Alon, I. (2017) ‘Bibliometric analysis of absorptive capacity’, International Business Review, 26, pp.896–907.

[2] Baba, Y., Shichijo, N. and Sedita, S. (2009) ‘How do collaborations with universities affect firms’ innovative performance? The role of “Pasteur scientists” in the advanced materials field', Research Policy, 38, 5, pp.756–64.

[3] Bioscience Innovation and Growth Team (2004) Bioscience 2015 Entire Executive Summary, available from www.bioindustry.org/bigtreport/index2.html (accessed November 2011).

[4] Cockburn, I. and Henderson, R. (1996) ‘Public-private interaction in pharmaceutical research’, Proceedings of the National Academy of Sciences, 93, 239, pp.12725–30.

[5] Cockburn, I. and Henderson, R. (1998) ‘Absorptive capacity, coauthoring behavior, and the organization of research in drug discovery’, Journal of Industrial Economics, 46, 2, pp.157–82.

[6] Cohen, W. and Levinthal, D. (1990) ‘Absorptive capacity: a new perspective on learning and innovation’, Administrative Sciences Quarterly, 35, pp.569–96.

[7] Comroe, J. and Dripps, R. (1976) ‘Scientific basis for the support of biomedical science’, Science, 192, 4235, pp.105–11.

[8] Cook, D., Brown D., Alexander, R. et al. (2014) ‘Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework’ Nature Reviews Drug Discovery, 13, pp.419–31.

[9] DiMasi, J., Feldman, L., Seckler, A. and Wilson, A. (2010) ‘Trends in risks associated with new drug development: success rates for investigational drugs’, Clinical Pharmacology and Therapeutics, 87, pp.272–7.

[10] Dimitrov, D. and Marks, J. (2009) ‘Therapeutic antibodies: current state and future trends – is a paradigm change coming soon?‘, Methods in Molecular Biology, 525, pp. 1–27.

[11] Edmondson, A. and McManus, S. (2007) ‘Methodological fit in management field research’, Academy of Management Review, 32, 4, pp.1246–64.

[12] Eisenhardt, K. and Graebner, M. (2007) ‘Theory building from cases: opportunities and challenges’, Academy of Management Journal, 50, 1, pp.25–32.

[13] Erlanson, D., Fesik, S., Hubbard, R. et al. (2016) ‘Twenty years on: the impact of fragments on drug discovery’, Nature Reviews Drug Discovery, 15, 9, pp.605–19.

[14] Fabrizio, K. (2009) ‘Absorptive capacity and the search for innovation’, Research Policy, 38, 2, pp.255–67.

[15] Fabrizio, K. and Di Minin, A. (2008) ‘Commercializing the laboratory: faculty patenting and the open science environment’, Research Policy, 37, 5, pp.914–31.

[16] Folkersen, L., Biswas, S., Frederiksen, K. et al. (2015) ‘Applying genetics in inflammatory disease drug discovery’, Drug Discovery Today, 20, 10, pp.1176–81.

[17] Furukawa, R. and Goto, A. (2006) ‘The role of corporate scientists in innovation’, Research Policy, 35, 1, pp.24–36.

[18] Galizzi, J., Lockhart, B. and Bril, A. (2013) ‘Applying systems biology in drug discovery and development’, Drug Metabolism and Drug Interactions, 28, 2, pp.67–78.

[19] Gittelman, M. (2016) ‘The revolution re-visited: clinical and genetics research paradigms and the productivity paradox in drug discovery’, Research Policy, 45, 8, pp.1570–85.

[20] Gittelman, M. and Kogut, B. (2003) ‘Does good science lead to valuable knowledge? Biotechnology firms and the evolutionary logic of citation patterns’, Management Science, 49, 4, pp.366–82.

[21] Hertzberg, R. and Pope, A. (2000) ‘High-throughput screening: new technology for the 21st century’, Current Opinion in Chemical Biology, 4, 4, pp.445–51.

[22] Hess, A. and Rothaermel, F. (2011) ‘When are assets complementary? Star scientists, strategic alliances, and innovation in the pharmaceutical industry’, Strategic Management Journal, 32, 8, pp.895–909.

[23] Hirano, T., Yasukawa, K., Harada, H. et al. (1986) ‘Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin’, Nature, 324, 6092, pp.73–6.

[24] Holmes, A., Bonner, F. and Jones, D. (2015) ‘Assessing drug safety in human tissues – what are the barriers?‘, Nature Reviews Drug Discovery, 14, pp.585–7.

[25] Japanese Society of Interferon and Cytokine Research (2010) Cytokine Hunting, Kyoto University Press, Kyoto (in Japanese).

[26] Kirchmair, J., Göller, A., Lang, D. et al. (2015) ‘Predicting drug metabolism: experiment and/or computation?‘, Nature Reviews Drug Discovery, 14, pp.387–404.

[27] Kishimoto, T. (2005) ‘Interleukin-6: from basic science to medicine – 40 years in immunology’, Annual Review of Immunology, 23, pp.1–21.

[28] Kishimoto, T. and Nakashima, A. (2007) Present Immunology Stories, Kodansha Publishing, Tokyo (in Japanese).

[29] Kishimoto, T. and Nakashima, A. (2009) Miracle of Antibody Medicine and Innate Immunity, Kodansha Publishing, Tokyo (in Japanese).

[30] Kuwashima, K. (2006) Management of Uncertainty, Nikkei BP Publishing, Tokyo (in Japanese).

[31] Morgan, P., Brown, D., Lennard, S. et al. (2018) ‘Impact of a five-dimensional framework on R&D productivity at AstraZeneca’, Nature Reviews Drug Discovery, 17, pp.167–81.

[32] Munos, B. (2009) ‘Lessons from 60 years of pharmaceutical innovation’, Nature Reviews Drug Discovery, 8, pp.959–68.

[33] Munos, B. (2016) ‘Biomedical innovation: lessons from the past and perspectives for the future’, Clinical Pharmacology and Therapeutics, 100, 6, pp.588–90.

[34] Nadeau, J. and Dudley, A. (2011) ‘Systems genetics’, Science, 331, pp.1015–16.

[35] Nagano, K. and Higashisaka, K. (2016) ‘Promotion of drug discovery research by utilizing omics technology’, Yakugaku Zasshi, 136, 2, pp.143–4.

[36] Nagaoka, S. (2016) New Drug Discovery and Development, Nikkei BP Publishing, Tokyo (in Japanese).

[37] Nishimoto, N. (2006) ‘Interleukin-6 in rheumatoid arthritis’, Current Opinion of Rheumatology, 18, 3, pp.277–81.

[38] Ohsugi, Y. (2007) ‘Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody) unveils the mysterious etiology of immune-mediated inflammatory diseases’, Biological and Pharmaceutical Bulletin, 30, 11, pp.2001–6.

[39] Ohsugi, Y. (2013) Birth of New Drug Actemra, Iwanami Shoten Publishing, Tokyo (in Japanese).

[40] Okuyama, R. (2017) ‘Importance of tacit knowledge in incremental innovation: implications from drug discovery cases’, Journal of Strategy and Management, 10, 1, pp.118–30.

[41] Plymoth, A. and Hainaut, P. (2011) ‘Proteomics beyond proteomics: toward clinical applications’, Current Opinion in Oncology, 23, 1, pp.77–82.

[42] Powell, W., Koput, K. and Smith-Doerr, L. (1996) ‘Interorganizational collaboration and the locus of innovation: networks of learning in biotechnology’, Administrative Science Quarterly, 41, 1, pp.116–45.

[43] Rosenberg, N. and Nelson, R. (1994) ‘American universities and technological advance in industry’, Research Policy, 23, 3, pp.323–48.

[44] Savino, R., Paduano, S., Preianò, M. and Terracciano, R. (2012) ‘The proteomics big challenge for biomarkers and new drug-targets discovery’, International Journal of Molecular Sciences, 13, 11, pp.13926–48.

[45] Scannell, J. Blanckley, A., Boldon, H. and Warrington, B. (2012) ‘Diagnosing the decline in pharmaceutical R&D efficiency’, Nature Reviews Drug Discovery, 11, pp.191–200.

[46] Smietana, K., Siatkowski, M. and Moller, M. (2016) ‘Trends in clinical success rates’, Nature Reviews Drug Discovery, 15, pp.379–80.

[47] Stokes, D. (1997) Pasteur's Quadrant: Basic Science and Technological Innovation, Brookings Institution, Washington, DC.

[48] Stranger, B., Stahl, E. and Raj, T. (2011) ‘Progress and promise of genome-wide association studies for human complex trait genetics’, Genetics, 187, pp.367–83.

[49] Swinney, D. and Anthony, J. (2011) ‘How were new medicines discovered?‘, Nature Reviews Drug Discovery, 10, pp.507–19.

[50] Tralau-Stewart, C., Wyatt, C., Kleyn, D. and Ayad, A. (2009) ‘Drug discovery: new models for industry–academic partnerships’, Drug Discovery Today, 14, 1/2, pp.95–101.

[51] Toole, A. (2012) ‘The impact of public basic research on industrial innovation: evidence from the pharmaceutical industry’, Research Policy, 41, 1, pp.1–12.

[52] Varmus, H. (2010) ‘Ten years on – the human genome and medicine’, New England Journal of Medicine, 362, 21, pp.2028–9.

[53] Van der Sijde, M., Ng, A. and Fu, J. (2014) ‘Systems genetics: from GWAS to disease pathways’, Biochimica et Biophysica Acta, 1842, 10, pp.1903–9.

[54] Yan, S., Liu, R., Jin, H. et al. (2015) ‘“Omics” in pharmaceutical research: overview, applications, challenges, and future perspectives’, Chinese Journal of Natural Medicines, 13, 1, pp.3–21.

[55] Zahra, S. and George, G. (2002) ‘Absorptive capacity: a review, reconceptualization, and extension’, Academy of Management Review, 27, 2, pp.185–203.

[56] Zucker. L., Darby, M. and Armstrong, J. (2002) ‘Commercializing knowledge: university science, knowledge capture, and firm performance in biotechnology’, Management Science, 48, 1, pp.138–53.